Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
Clinical trial NCT05308225 · UNKNOWN
Trial details
- NCT number
- NCT05308225
- Sponsor
- Sorrento Therapeutics, Inc.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-01
- Primary completion
- 2025-12-01
- Enrollment
- 72
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.